GLYC Key Stats
- GlycoMimetics to Present GMI-1271 Research Findings at AACR Annual Meeting 2014 Business Wire 03/05 09:15 ET
- Vista Partners Updates Coverage on Mast Therapeutics, Inc. (NYSE MKT: MSTX); Price Target $2.25 Marketwired 02/28 09:00 ET
- Biotechs Dominate IPO Calendar, But Most Post Negative Returns Seeking Alpha 02/06 11:45 ET
- Jefferies Starts Glycomimetics (GLYC) at Buy Street Insider 02/04 07:53 ET
- Coverage initiated on GlycoMimetics by Stifel and Barclays Yahoo 02/04 07:13 ET
- Stifel Nicolaus Starts Glycomimetics (GLYC) at Buy Street Insider 02/04 07:06 ET
- Barclays Starts Glycomimetics (GLYC) at Overweight Street Insider 02/04 07:06 ET
- Canaccord Genuity Starts Glycomimetics (GLYC) at Buy Street Insider 02/04 07:05 ET
- GlycoMimetics to Present at BIO CEO & Investor Conference Business Wire 02/03 16:00 ET
- Stocks: Insiders Buy at DDR Corp and GlycoMimetics; Wendy's Sees a Huge Sale Minyanville 01/16 11:10 ET
GLYC Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). GlycoMimetics is up N/A over the last year vs S&P 500 Total Return up 24.21%, uniQure up N/A, and Ultragenyx Pharmaceutical up N/A.
Balance Sheet View Statement
Pro Ratings for GLYC
Pro Strategies Featuring GLYC
Did GlycoMimetics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: Maryland
- Incorporation Country: United States
- Incorporation State/Province: Delaware
GlycoMimetics Inc is a clinical stage biotechnology company engaged in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.